Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...

Seven students from among more than 300 entrants from the Loudoun County Public Schools Regional Science and Engineering Fair ...

Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis ...

New RNA-based active agents reliably protect plants against the Cucumber mosaic virus (CMV), the most common virus in ...

The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...

SHANGHAI, China I March 17, 2025 I Rona Therapeutics Inc., a global leader in RNA-targeted therapeutics, announced the clearance of an Investigational New ...

Researchers at Martin Luther University have developed groundbreaking RNA-based agents that offer high levels of protection ...

A new study published in the Journal of American Medical Association showed that the innovative small interfering RNA (siRNA) medication olpasiran (Amgen) can effectively reduce lipoprotein(a) ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

Privately-held Chinese firm Visirna Therapeutics has announced that a Phase III trial of VSA001 (plozasiran) has met both its ...

New injectable hydrogel regulates immune cell metabolism, reducing inflammation and slowing rheumatoid arthritis progression.